Ascendis’s Yorvipath Approved By FDA For Hypoparathyroidism But US Launch Delayed
Yorvipath Will Fill Gap Left By Takeda’s Natpara
The US launch of Yorvipath will be delayed until Q4 2024 or early 2025 due to manufacturing, though the drug is already available in some European countries.
